{"title":"MSMO1 的上调与宫颈癌患者的生存率低有关。","authors":"Jing Zou, Sha Liu, Jian Long","doi":"10.21037/tcr-24-243","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Methylsterol monooxygenase 1 (MSMO1) catalyzes C4-methylsterols demethylation in cholesterol biosynthesis pathway. MSMO1 is increased and up-regulation of MSMO1 is correlated with progression of some tumor. But the correlation of MSMO1 to cervical cancer is unknown. The current study aimed to explore the expression pattern of MSMO1 in cervical cancer and its correlation to clinical characteristics.</p><p><strong>Methods: </strong>In this study, 306 cervical cancer cases and 13 non-tumor cases were included. We compared MSMO1 expression level in non-tumor cervical tissues and cervical cancer samples using the Wilcoxon rank sum test. Univariate regression was used to investigate the correlation between MSMO1 expression as well as other clinical characteristics and prognosis. Clinical characteristics associated with prognosis in univariate analysis were used as adjustments for multivariate analysis to further validate the relationship between MSMO1 expression and cervical cancer prognosis. Patients' survival in different subgroups was compared by Kaplan-Meier (KM) method. The potential protein interaction was analyzed. T cell infiltration level in MSMO1 high and low group patients was compared.</p><p><strong>Results: </strong>MSMO1 expression level was up-regulated in cervical cancer (P<0.001). Patients who had stage III-IV diseases (P=0.04) and did not achieve complete response after primary treatment had higher MSMO1 expression (P<0.001). High MSMO1 expression patients showed a lower overall survival (OS) (P=0.004), disease-specific survival (DSS) (P=0.004) and progression-free survival (PFS) (P=0.002). High MSMO1 expression was a risk factor to OS (P=0.01), DSS (P=0.009) and PFS (P=0.009). Multiple variate analysis showed that high MSMO1 expression was an independent risk factor to OS [hazard ratio (HR) =1.902, 95% confidence interval (CI): 1.156-3.129, P=0.01], DSS (HR =2.172, 95% CI: 1.210-3.897, P=0.009) and PFS (HR =1.975, 95% CI: 1.189-3.282, P=0.009) in cervical squamous cell carcinoma (CESC). The prognostic value of high MSMO1 expression was further examined in other databases, including KM-plotter, Gene Expression Profiling Interactive Analysis (GEPIA) and Gene Expression Omnibus (GEO) database.</p><p><strong>Conclusions: </strong>The current research showed that MSMO1 was increased and was associated with poor prognosis in CESC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 10","pages":"5316-5327"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543037/pdf/","citationCount":"0","resultStr":"{\"title\":\"Up-regulation of MSMO1 was associated with poor survival in cervical cancer.\",\"authors\":\"Jing Zou, Sha Liu, Jian Long\",\"doi\":\"10.21037/tcr-24-243\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Methylsterol monooxygenase 1 (MSMO1) catalyzes C4-methylsterols demethylation in cholesterol biosynthesis pathway. MSMO1 is increased and up-regulation of MSMO1 is correlated with progression of some tumor. But the correlation of MSMO1 to cervical cancer is unknown. The current study aimed to explore the expression pattern of MSMO1 in cervical cancer and its correlation to clinical characteristics.</p><p><strong>Methods: </strong>In this study, 306 cervical cancer cases and 13 non-tumor cases were included. We compared MSMO1 expression level in non-tumor cervical tissues and cervical cancer samples using the Wilcoxon rank sum test. Univariate regression was used to investigate the correlation between MSMO1 expression as well as other clinical characteristics and prognosis. Clinical characteristics associated with prognosis in univariate analysis were used as adjustments for multivariate analysis to further validate the relationship between MSMO1 expression and cervical cancer prognosis. Patients' survival in different subgroups was compared by Kaplan-Meier (KM) method. The potential protein interaction was analyzed. T cell infiltration level in MSMO1 high and low group patients was compared.</p><p><strong>Results: </strong>MSMO1 expression level was up-regulated in cervical cancer (P<0.001). Patients who had stage III-IV diseases (P=0.04) and did not achieve complete response after primary treatment had higher MSMO1 expression (P<0.001). High MSMO1 expression patients showed a lower overall survival (OS) (P=0.004), disease-specific survival (DSS) (P=0.004) and progression-free survival (PFS) (P=0.002). High MSMO1 expression was a risk factor to OS (P=0.01), DSS (P=0.009) and PFS (P=0.009). Multiple variate analysis showed that high MSMO1 expression was an independent risk factor to OS [hazard ratio (HR) =1.902, 95% confidence interval (CI): 1.156-3.129, P=0.01], DSS (HR =2.172, 95% CI: 1.210-3.897, P=0.009) and PFS (HR =1.975, 95% CI: 1.189-3.282, P=0.009) in cervical squamous cell carcinoma (CESC). The prognostic value of high MSMO1 expression was further examined in other databases, including KM-plotter, Gene Expression Profiling Interactive Analysis (GEPIA) and Gene Expression Omnibus (GEO) database.</p><p><strong>Conclusions: </strong>The current research showed that MSMO1 was increased and was associated with poor prognosis in CESC.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"13 10\",\"pages\":\"5316-5327\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543037/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-24-243\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-243","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Up-regulation of MSMO1 was associated with poor survival in cervical cancer.
Background: Methylsterol monooxygenase 1 (MSMO1) catalyzes C4-methylsterols demethylation in cholesterol biosynthesis pathway. MSMO1 is increased and up-regulation of MSMO1 is correlated with progression of some tumor. But the correlation of MSMO1 to cervical cancer is unknown. The current study aimed to explore the expression pattern of MSMO1 in cervical cancer and its correlation to clinical characteristics.
Methods: In this study, 306 cervical cancer cases and 13 non-tumor cases were included. We compared MSMO1 expression level in non-tumor cervical tissues and cervical cancer samples using the Wilcoxon rank sum test. Univariate regression was used to investigate the correlation between MSMO1 expression as well as other clinical characteristics and prognosis. Clinical characteristics associated with prognosis in univariate analysis were used as adjustments for multivariate analysis to further validate the relationship between MSMO1 expression and cervical cancer prognosis. Patients' survival in different subgroups was compared by Kaplan-Meier (KM) method. The potential protein interaction was analyzed. T cell infiltration level in MSMO1 high and low group patients was compared.
Results: MSMO1 expression level was up-regulated in cervical cancer (P<0.001). Patients who had stage III-IV diseases (P=0.04) and did not achieve complete response after primary treatment had higher MSMO1 expression (P<0.001). High MSMO1 expression patients showed a lower overall survival (OS) (P=0.004), disease-specific survival (DSS) (P=0.004) and progression-free survival (PFS) (P=0.002). High MSMO1 expression was a risk factor to OS (P=0.01), DSS (P=0.009) and PFS (P=0.009). Multiple variate analysis showed that high MSMO1 expression was an independent risk factor to OS [hazard ratio (HR) =1.902, 95% confidence interval (CI): 1.156-3.129, P=0.01], DSS (HR =2.172, 95% CI: 1.210-3.897, P=0.009) and PFS (HR =1.975, 95% CI: 1.189-3.282, P=0.009) in cervical squamous cell carcinoma (CESC). The prognostic value of high MSMO1 expression was further examined in other databases, including KM-plotter, Gene Expression Profiling Interactive Analysis (GEPIA) and Gene Expression Omnibus (GEO) database.
Conclusions: The current research showed that MSMO1 was increased and was associated with poor prognosis in CESC.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.